Search
Descriptor English: Natalizumab
Descriptor Spanish: Natalizumab
Descriptor natalizumab
Scope note: Un anticuerpo monoclonal humanizado G4 inmunoglobulina para INTEGRINA ALFA4 humana que se une a la subunidad alfa 4 de INTEGRINA ALFA4BETA1 y ALFA4BETA7 integrina. Se utiliza como FACTORES INMUNOLÓGICOS en el tratamiento de la ESCLEROSIS MÚLTIPLE RECURRENTE-REMITENTE y ENFERMEDAD de CROHN.
Descriptor Portuguese: Natalizumab
Descriptor French: Natalizumab
Entry term(s): Antegren
Tysabri
Tree number(s): D12.776.124.486.485.114.224.060.813
D12.776.124.790.651.114.224.060.813
D12.776.377.715.548.114.224.200.813
RDF Unique Identifier: https://id.nlm.nih.gov/mesh/D000069442
Scope note: A humanized monoclonal immunoglobulin G4 antibody to human INTEGRIN ALPHA4 that binds to the alpha4 subunit of INTEGRIN ALPHA4BETA1 and integrin alpha4beta7. It is used as an IMMUNOLOGIC FACTOR in the treatment of RELAPSING-REMITTING MULTIPLE SCLEROSIS and CROHN'S DISEASE.
Allowable Qualifiers: AD administration & dosage
AE adverse effects
AN analysis
BI biosynthesis
BL blood
CF cerebrospinal fluid
CH chemistry
CL classification
DE drug effects
EC economics
GE genetics
HI history
IM immunology
IP isolation & purification
ME metabolism
PD pharmacology
PH physiology
PK pharmacokinetics
PO poisoning
RE radiation effects
TO toxicity
TU therapeutic use
UL ultrastructure
UR urine
Pharm Action: Immunologic Factors
Public MeSH Note: 2016; NATALIZUMAB was indexed under ANTIBODIES, MONOCLONAL, HUMANIZED 2011-2015 and under ANTIBODIES, MONOCLONAL 2002-2011
History Note: 2016 (2002)
Related: Integrin alpha4 MeSH
DeCS ID: 55977
Unique ID: D000069442
Documents indexed in the Virtual Health Library (VHL): Click here to access the VHL documents
Date Established: 2016/01/01
Date of Entry: 2015/07/06
Revision Date: 2015/06/26
Natalizumab - Preferred
Concept UI M0443607
Scope note A humanized monoclonal immunoglobulin G4 antibody to human INTEGRIN ALPHA4 that binds to the alpha4 subunit of INTEGRIN ALPHA4BETA1 and integrin alpha4beta7. It is used as an IMMUNOLOGIC FACTOR in the treatment of RELAPSING-REMITTING MULTIPLE SCLEROSIS and CROHN'S DISEASE.
Preferred term Natalizumab
Tysabri - Narrower
Concept UI M0477090
Preferred term Tysabri
Antegren - Narrower
Concept UI M0444257
Preferred term Antegren



We want your feedback on the new DeCS / MeSH website

We invite you to complete a survey that will take no more than 3 minutes.

Go to survey